Get the Stockscreener App
97.68
1.68%
1.61
After Hours:
97.37
-0.31
-0.32%
Illumina Inc stock is traded at $97.68, with a volume of 1.14M.
It is up +1.68% in the last 24 hours and down -0.77% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$96.07
Open:
$95.86
24h Volume:
1.14M
Relative Volume:
0.55
Market Cap:
$15.01B
Revenue:
$4.28B
Net Income/Loss:
$1.26B
P/E Ratio:
12.36
EPS:
7.9
Net Cash Flow:
$943.00M
1W Performance:
-1.50%
1M Performance:
-0.77%
6M Performance:
+15.07%
1Y Performance:
-24.04%
1-Day Range:
$93.94
$97.92
1-Week Range:
$93.94
$100.44
52-Week Range:
$68.70
$156.66
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
97.68 | 15.48B | 4.28B | 1.26B | 943.00M | 7.90 |
|
TMO
Thermo Fisher Scientific Inc
|
489.49 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
199.03 | 145.92B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
640.44 | 51.16B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
128.48 | 35.50B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
184.08 | 31.24B | 15.70B | 1.24B | 2.01B | 6.91 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Carl Icahn Exits Dana And Illumina: Capital Redeployment Signals Portfolio Repositioning - The Acquirer's Multiple
What the charts say about Illumina Inc. todayPortfolio Return Summary & Long-Term Capital Growth Ideas - Newser
Illumina Protein Prep: Revolutionizing Proteomics to Accelerate Drug Discovery and ROI for Biopharma - AInvest
Illumina Protein Prep launches to drive greater proteomic insights for improved drug discovery and development - MarketScreener
Can machine learning forecast Illumina Inc. recoveryMarket Growth Summary & Free Weekly Chart Analysis and Trade Guides - Newser
Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development - PR Newswire
Will Illumina Inc. benefit from macro trendsEarnings Beat & Risk Controlled Stock Alerts - Newser
Real time social sentiment graph for Illumina Inc.July 2025 Analyst Calls & Weekly High Momentum Picks - Newser
RBC Trims Price Target on Illumina to $124 From $126, Keeps Outperform Rating - MarketScreener
Regression analysis insights on Illumina Inc. performance2025 Winners & Losers & High Win Rate Trade Tips - Newser
Will Illumina Inc. continue its uptrendTrade Analysis Report & Momentum Based Trading Ideas - Newser
What institutional flow reveals about Illumina Inc.2025 Short Interest & Verified Short-Term Trading Plans - Newser
Illumina Inc. Stock Underperforms Tuesday When Compared To Competitors - 富途牛牛
Can Illumina Inc. stock double in the next year2025 Market WrapUp & Precise Swing Trade Entry Alerts - khodrobank.com
Pattern recognition hints at Illumina Inc. upsideStop Loss & Growth Focused Investment Plans - Newser
Using data filters to optimize entry into Illumina Inc.Insider Buying & Accurate Entry/Exit Alerts - Newser
Why Illumina Inc. is moving todayJuly 2025 Pullbacks & High Accuracy Investment Signals - Newser
Chart based exit strategy for Illumina Inc.Layoff News & AI Based Buy and Sell Signals - Newser
Is Illumina Inc. stock overvalued or fairly pricedJuly 2025 Review & Risk Controlled Daily Plans - khodrobank.com
Best data tools to analyze Illumina Inc. stockGap Down & Fast Moving Stock Watchlists - Newser
Should I hold or sell Illumina Inc. nowJuly 2025 Breakouts & Daily Risk Controlled Trade Plans - khodrobank.com
Expanding possibilities: Illumina’s innovative leap forward in genome sequencing - Illumina
Measuring Illumina Inc.’s beta against major indicesJuly 2025 Price Swings & Reliable Price Breakout Signals - Newser
Hardening Software Security: DOJ’s Civil Cyber Fraud Settlements Continue to Illumina[te] the Importance of Cybersecurity - governmentcontractslegalforum.com
Published on: 2025-09-02 10:12:20 - Newser
Volume spikes in Illumina Inc. stock – what they mean2025 Retail Activity & Stepwise Trade Signal Implementation - Newser
Forecasting Illumina Inc. price range with options dataJuly 2025 Analyst Calls & Real-Time Stock Price Movement Reports - Newser
What’s next for Illumina Inc. stockQuarterly Trade Report & Consistent Profit Trading Strategies - khodrobank.com
Illumina (ILMN) Outpaces Expectations Despite Revenue Dip Could Be a Game Changer for Growth Narrative - Yahoo Finance
Top chart patterns to watch in Illumina Inc.Watch List & Safe Capital Investment Plans - Newser
Liquid Biopsy Market Trends and Industry Forecast to 2030 - GlobeNewswire
Liquid Biopsy Market Trends and Industry Forecast to 2030 Featuring Strategic Analysis of Natera, Guardant Health, Myriad Genetics, Illumina, and Roche Among Others - Yahoo Finance
How does Illumina Inc. perform in inflationary periodsWeekly Stock Analysis & Community Consensus Trade Signals - khodrobank.com
Can Illumina Inc. hit a new high this monthJuly 2025 Breakouts & Fast Gain Swing Alerts - Newser
Will Illumina Inc. announce a stock splitJuly 2025 Spike Watch & Real-Time Volume Analysis Alerts - khodrobank.com
Illumina Inc. stock trend forecastMarket Growth Review & Free Technical Pattern Based Buy Signals - Newser
Take Profit: Is Illumina Inc. stock influenced by commodity pricesJuly 2025 Snapshot & Verified Entry Point Signals - khodrobank.com
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term - sharewise.com
Can Illumina Inc. benefit from deglobalizationQuarterly Risk Review & Reliable Intraday Trade Plans - khodrobank.com
What are analysts’ price targets for Illumina Inc.July 2025 Movers & Technical Buy Zone Confirmations - khodrobank.com
Ranking Illumina Inc. among high performing stocks via toolsQuarterly Profit Review & Weekly High Potential Stock Alerts - Newser
Detecting price anomalies in Illumina Inc. with AIJuly 2025 Rallies & High Yield Stock Recommendations - Newser
Illumina Inc. stock daily chart insightsJuly 2025 Closing Moves & Momentum Based Trading Signals - Newser
Smart tools for monitoring Illumina Inc.’s price actionMarket Performance Report & Reliable Entry Point Alerts - Newser
Can you recover from losses in Illumina Inc.July 2025 News Drivers & Safe Entry Trade Signal Reports - Newser
Aug Weekly: Will Illumina Inc. announce a stock split2025 Volatility Report & Risk Managed Trade Strategies - khodrobank.com
What momentum shifts mean for Illumina Inc.July 2025 Gainers & Consistent Growth Equity Picks - Newser
Custom watchlist performance reports with Illumina Inc.Fed Meeting & Low Drawdown Trading Strategies - Newser
Life Sciences Tools & Services Stocks Q2 Results: Benchmarking Illumina (NASDAQ:ILMN) - FinancialContent
Risk adjusted return profile for Illumina Inc. analyzedPortfolio Performance Report & Long-Term Growth Portfolio Plans - Newser
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Illumina Inc Stock (ILMN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thaysen Jacob | Chief Executive Officer |
May 12 '25 |
Buy |
80.88 |
6,500 |
525,732 |
77,540 |
| Thaysen Jacob | Chief Executive Officer |
May 13 '25 |
Buy |
80.84 |
5,850 |
472,942 |
83,390 |
3.32%
0.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):